Forte Ebit Per Revenue vs Revenue Per Share Analysis

FBRX Stock

USD 15.99 1.29 8.78%

Forte Biosciences financial indicator trend analysis is much more than just examining Forte Biosciences latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Forte Biosciences is a good investment. Please check the relationship between Forte Biosciences Ebit Per Revenue and its Revenue Per Share accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Forte Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Forte Stock please use our How to Invest in Forte Biosciences guide.

Ebit Per Revenue vs Revenue Per Share

Ebit Per Revenue vs Revenue Per Share Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Forte Biosciences Ebit Per Revenue account and Revenue Per Share. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Forte Biosciences' Ebit Per Revenue and Revenue Per Share is 0.92. Overlapping area represents the amount of variation of Ebit Per Revenue that can explain the historical movement of Revenue Per Share in the same time period over historical financial statements of Forte Biosciences, assuming nothing else is changed. The correlation between historical values of Forte Biosciences' Ebit Per Revenue and Revenue Per Share is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Ebit Per Revenue of Forte Biosciences are associated (or correlated) with its Revenue Per Share. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Revenue Per Share has no effect on the direction of Ebit Per Revenue i.e., Forte Biosciences' Ebit Per Revenue and Revenue Per Share go up and down completely randomly.

Correlation Coefficient

0.92

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Ebit Per Revenue

Revenue Per Share

The amount of revenue generated by a company per share of stock, calculated by dividing total revenue by the average number of shares outstanding.

Most indicators from Forte Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Forte Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Forte Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Forte Stock please use our How to Invest in Forte Biosciences guide.Issuance Of Capital Stock is likely to rise to about 23.4 M in 2025, whereas Selling General Administrative is likely to drop slightly above 7.6 M in 2025.

	2023	2024	2025 (projected)
Depreciation And Amortization	9K	8.1K	7.7K
Interest Income	1.1M	1.3M	1.3M

Depreciation And Amortization Interest Income

Forte Biosciences fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Long Term Debt Total	Non Current Liabilities Total	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets
Total Assets		0.55	0.57	0.65	0.81	0.71	-0.06	-0.64	0.58	0.34	0.71	0.04	0.36	-0.42	1.0	0.9	-0.23	0.84	-0.42	0.48	-0.2	0.82	0.71	0.62	0.71	1.0
Short Long Term Debt Total	0.55		0.8	0.61	0.02	0.68	0.6	-0.47	0.57	-0.3	0.9	0.73	0.88	-0.36	0.52	0.31	0.3	0.7	-0.36	0.9	-0.66	0.55	0.65	0.92	0.68	0.52
Other Current Liab	0.57	0.8		0.93	0.12	0.78	0.35	-0.74	0.74	-0.07	0.85	0.41	0.63	-0.47	0.54	0.25	0.18	0.49	-0.47	0.6	-0.33	0.64	0.72	0.82	0.78	0.54
Total Current Liabilities	0.65	0.61	0.93		0.3	0.76	0.2	-0.77	0.76	0.06	0.71	0.15	0.43	-0.6	0.63	0.35	0.13	0.51	-0.6	0.44	-0.17	0.7	0.65	0.73	0.76	0.64
Total Stockholder Equity	0.81	0.02	0.12	0.3		0.34	-0.49	-0.53	0.24	0.6	0.24	-0.42	-0.16	-0.2	0.83	0.88	-0.62	0.51	-0.2	-0.08	0.17	0.62	0.46	0.05	0.34	0.82
Property Plant And Equipment Net	0.71	0.68	0.78	0.76	0.34		0.06	-0.71	0.97	0.24	0.88	0.16	0.34	-0.07	0.69	0.54	0.2	0.5	-0.07	0.63	0.06	0.53	0.75	0.77	1.0	0.69
Net Debt	-0.06	0.6	0.35	0.2	-0.49	0.06		-0.05	0.04	-0.93	0.28	0.63	0.75	-0.4	-0.09	-0.18	0.74	0.41	-0.4	0.64	-0.77	0.24	0.21	0.58	0.06	-0.08
Retained Earnings	-0.64	-0.47	-0.74	-0.77	-0.53	-0.71	-0.05		-0.68	-0.1	-0.59	0.18	-0.18	0.26	-0.63	-0.56	0.09	-0.44	0.26	-0.2	-0.05	-0.69	-0.87	-0.45	-0.71	-0.63
Accounts Payable	0.58	0.57	0.74	0.76	0.24	0.97	0.04	-0.68		0.22	0.77	0.08	0.21	-0.03	0.56	0.39	0.3	0.34	-0.03	0.52	0.18	0.45	0.66	0.69	0.97	0.56
Cash	0.34	-0.3	-0.07	0.06	0.6	0.24	-0.93	-0.1	0.22		0.06	-0.43	-0.5	0.28	0.36	0.37	-0.71	-0.16	0.28	-0.34	0.64	-0.03	0.01	-0.25	0.24	0.35
Non Current Assets Total	0.71	0.9	0.85	0.71	0.24	0.88	0.28	-0.59	0.77	0.06		0.55	0.7	-0.19	0.68	0.47	0.14	0.64	-0.19	0.82	-0.34	0.63	0.76	0.9	0.87	0.68
Non Currrent Assets Other	0.04	0.73	0.41	0.15	-0.42	0.16	0.63	0.18	0.08	-0.43	0.55		0.85	-0.2	0.01	-0.23	0.33	0.31	-0.2	0.75	-0.76	0.15	0.06	0.62	0.16	0.02
Other Assets	0.36	0.88	0.63	0.43	-0.16	0.34	0.75	-0.18	0.21	-0.5	0.7	0.85		-0.46	0.33	0.13	0.32	0.67	-0.46	0.85	-0.88	0.5	0.45	0.82	0.34	0.34
Long Term Debt	-0.42	-0.36	-0.47	-0.6	-0.2	-0.07	-0.4	0.26	-0.03	0.28	-0.19	-0.2	-0.46		-0.42	-0.17	-0.05	-0.59	1.0	-0.24	0.61	-0.56	-0.14	-0.42	-0.07	-0.42
Cash And Short Term Investments	1.0	0.52	0.54	0.63	0.83	0.69	-0.09	-0.63	0.56	0.36	0.68	0.01	0.33	-0.42		0.91	-0.25	0.83	-0.42	0.46	-0.18	0.82	0.69	0.59	0.69	1.0
Common Stock Total Equity	0.9	0.31	0.25	0.35	0.88	0.54	-0.18	-0.56	0.39	0.37	0.47	-0.23	0.13	-0.17	0.91		-0.3	0.76	-0.17	0.29	-0.03	0.67	0.68	0.36	0.54	0.91
Common Stock Shares Outstanding	-0.23	0.3	0.18	0.13	-0.62	0.2	0.74	0.09	0.3	-0.71	0.14	0.33	0.32	-0.05	-0.25	-0.3		0.08	-0.05	0.51	-0.24	-0.07	0.02	0.46	0.2	-0.25
Short Term Investments	0.84	0.7	0.49	0.51	0.51	0.5	0.41	-0.44	0.34	-0.16	0.64	0.31	0.67	-0.59	0.83	0.76	0.08		-0.59	0.71	-0.63	0.77	0.62	0.74	0.5	0.84
Long Term Debt Total	-0.42	-0.36	-0.47	-0.6	-0.2	-0.07	-0.4	0.26	-0.03	0.28	-0.19	-0.2	-0.46	1.0	-0.42	-0.17	-0.05	-0.59		-0.24	0.61	-0.56	-0.14	-0.42	-0.07	-0.42
Non Current Liabilities Total	0.48	0.9	0.6	0.44	-0.08	0.63	0.64	-0.2	0.52	-0.34	0.82	0.75	0.85	-0.24	0.46	0.29	0.51	0.71	-0.24		-0.64	0.42	0.5	0.93	0.63	0.46
Capital Surpluse	-0.2	-0.66	-0.33	-0.17	0.17	0.06	-0.77	-0.05	0.18	0.64	-0.34	-0.76	-0.88	0.61	-0.18	-0.03	-0.24	-0.63	0.61	-0.64		-0.37	-0.16	-0.55	0.06	-0.19
Other Current Assets	0.82	0.55	0.64	0.7	0.62	0.53	0.24	-0.69	0.45	-0.03	0.63	0.15	0.5	-0.56	0.82	0.67	-0.07	0.77	-0.56	0.42	-0.37		0.72	0.61	0.53	0.82
Other Stockholder Equity	0.71	0.65	0.72	0.65	0.46	0.75	0.21	-0.87	0.66	0.01	0.76	0.06	0.45	-0.14	0.69	0.68	0.02	0.62	-0.14	0.5	-0.16	0.72		0.64	0.75	0.69
Total Liab	0.62	0.92	0.82	0.73	0.05	0.77	0.58	-0.45	0.69	-0.25	0.9	0.62	0.82	-0.42	0.59	0.36	0.46	0.74	-0.42	0.93	-0.55	0.61	0.64		0.77	0.6
Property Plant And Equipment Gross	0.71	0.68	0.78	0.76	0.34	1.0	0.06	-0.71	0.97	0.24	0.87	0.16	0.34	-0.07	0.69	0.54	0.2	0.5	-0.07	0.63	0.06	0.53	0.75	0.77		0.69
Total Current Assets	1.0	0.52	0.54	0.64	0.82	0.69	-0.08	-0.63	0.56	0.35	0.68	0.02	0.34	-0.42	1.0	0.91	-0.25	0.84	-0.42	0.46	-0.19	0.82	0.69	0.6	0.69

Click cells to compare fundamentals

Forte Biosciences Account Relationship Matchups

Forte Biosciences fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	61.2M	43.3M	42.0M	39.0M	35.1M	43.2M
Other Current Liab	1.0M	812K	2.0M	2.2M	2.0M	4.0M
Total Current Liabilities	2.3M	1.8M	3.2M	3.7M	3.3M	6.0M
Total Stockholder Equity	59.0M	41.5M	38.8M	35.3M	40.6M	42.2M
Property Plant And Equipment Net	150.6K	97K	0.0	109K	98.1K	93.2K
Net Debt	(58.8M)	(42.0M)	(41.1M)	(12.0M)	(10.8M)	(11.3M)
Retained Earnings	(51.5M)	(73.2M)	(87.0M)	(118.5M)	(136.3M)	(143.1M)
Accounts Payable	1.2M	946K	1.2M	1.4M	1.3M	1.3M
Cash	58.8M	42.0M	41.1M	12.0M	13.8M	13.1M
Non Current Assets Total	1.3M	786K	486K	653K	587.7K	558.3K
Cash And Short Term Investments	58.8M	42.0M	41.1M	37.1M	33.4M	41.0M
Common Stock Shares Outstanding	294.4K	558.7K	695.3K	1.3M	1.1M	862.0K
Liabilities And Stockholders Equity	61.2M	43.3M	42.0M	39.0M	35.1M	43.2M
Non Current Liabilities Total	28.4M	10.5M	1.2M	946K	1.2M	0.0
Other Current Assets	1.1M	476K	411K	1.2M	1.1M	831.3K
Other Stockholder Equity	49.2M	71.4M	125.8M	153.8M	138.4M	96.1M
Total Liab	2.3M	1.8M	3.2M	3.7M	3.3M	3.1M
Property Plant And Equipment Gross	150.6K	97K	0.0	118K	106.2K	100.9K
Total Current Assets	59.9M	42.5M	41.5M	38.3M	34.5M	41.8M
Accumulated Other Comprehensive Income	10K	(61.2M)	(43.3M)	4K	3.6K	3.8K
Net Tangible Assets	(4.8M)	59.0M	41.5M	38.8M	44.6M	29.4M
Net Invested Capital	59.0M	41.5M	38.8M	35.3M	40.6M	37.4M
Capital Stock	13K	15K	21K	36K	41.4K	43.5K
Net Working Capital	57.6M	40.8M	38.3M	34.7M	39.9M	38.9M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

F	Ford Motor
GM	General Motors
S	SentinelOne

Additional Tools for Forte Stock Analysis

When running Forte Biosciences' price analysis, check to measure Forte Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Forte Biosciences is operating at the current time. Most of Forte Biosciences' value examination focuses on studying past and present price action to predict the probability of Forte Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Forte Biosciences' price. Additionally, you may evaluate how the addition of Forte Biosciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Forte Ebit Per Revenue vs Revenue Per Share Analysis

Ebit Per Revenue vs Revenue Per Share

Ebit Per Revenue vs Revenue Per Share Correlation Analysis

Correlation Coefficient

Ebit Per Revenue

Revenue Per Share

Forte Biosciences fundamental ratios Correlations

Forte Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Forte Biosciences fundamental ratios Accounts

Also Currently Popular

Additional Tools for Forte Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Long Term Debt Total	+ 1.0	Long Term Debt
Total Current Assets	+ 1.0	Cash And Short Term Investments
Accounts Payable	+ 0.97	Property Plant And Equipment Net

Cash	- 0.93	Net Debt
Capital Surpluse	- 0.88	Other Assets
Other Stockholder Equity	- 0.87	Retained Earnings
Capital Surpluse	- 0.77	Net Debt
Retained Earnings	- 0.77	Total Current Liabilities
Capital Surpluse	- 0.76	Non Currrent Assets Other